Ascentage Pharma
AAPG
14.94
-1.15
-7.15%
Ascentage Pharma
US · AAPG
#3045 by market cap
Listed 2025
14.94
-1.15
-7.15%
Live - 5344 symbols - heartbeat 94s ago
· 2026-10-08 08:27
Pre-market
14.70
-1.61%
After-hours
14.94
0.00%
Overnight
14.70
-1.61%
- Market cap
- 1.40B
- P/E (TTM)i
- -6.37
- P/Bi
- 16.81
- EPSi
- -1.99
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on AAPG?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 4 analysts
Buy
Avg price target
46.00 +207.9%
Price target rangecurrent 14.94
Low45.00
Avg46.00
High48.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-02 | B. Riley Securities | -- | BUY | 45.00 |
| 2026-08-21 | Truist Financial | -- | BUY | -- |
| 2026-08-21 | Oppenheimer | -- | BUY | 45.00 |
| 2026-08-20 | BTIG | -- | BUY | 48.00 |
| 2026-08-10 | Truist Financial | -- | BUY | -- |
| 2026-06-15 | Oppenheimer | -- | BUY | 45.00 |
| 2026-06-10 | B. Riley Securities | -- | BUY | 45.00 |
| 2026-06-01 | Piper Sandler | -- | BUY | 48.00 |
| 2026-05-13 | BTIG | -- | BUY | 48.00 |
| 2026-04-24 | Truist Financial | -- | BUY | 51.00 |
| 2026-04-22 | Piper Sandler | -- | BUY | 48.00 |
| 2026-04-15 | Piper Sandler | -- | BUY | 48.00 |
| 2026-04-15 | J.P. Morgan | -- | BUY | 46.00 |
| 2026-04-13 | BTIG | -- | BUY | 48.00 |
| 2026-04-10 | Piper Sandler | -- | BUY | 48.00 |
| 2026-03-27 | Truist Financial | -- | BUY | 51.00 |
| 2026-03-26 | BTIG | -- | BUY | 48.00 |
| 2026-03-12 | BTIG | -- | BUY | 48.00 |
| 2026-03-11 | BTIG | -- | BUY | 48.00 |
| 2026-01-08 | Piper Sandler | -- | BUY | 48.00 |
| 2025-12-15 | Lucid Capital | -- | BUY | 50.00 |
| 2025-12-12 | Piper Sandler | -- | BUY | 48.00 |
| 2025-12-08 | Piper Sandler | -- | BUY | 48.00 |
| 2025-12-04 | Oppenheimer | -- | BUY | 45.00 |
| 2025-12-02 | BTIG | -- | BUY | 50.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Actual move |
|---|---|---|---|
| 2026/Q2 | 2026-08-19 | -- | -0.93% |
| 2025/Q4 | 2026-03-25 | After close | -4.84% |
| 2025/Q2 | 2025-08-20 | After close | +1.05% |
| 2024/Q4 | 2025-03-27 | -- | +9.96% |
Quote time 2026-10-08 08:27:25 · For reference only, not investment advice and not tailored to your situation.